A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn’sDisease who have failed anti-TNF therapy
- Moore, Gregory (Primary Chief Investigator (PCI))
Project: Research